0001415889-23-016532.txt : 20231215
0001415889-23-016532.hdr.sgml : 20231215
20231215164021
ACCESSION NUMBER: 0001415889-23-016532
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231215
FILED AS OF DATE: 20231215
DATE AS OF CHANGE: 20231215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DIXON WENDY L
CENTRAL INDEX KEY: 0001202283
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39200
FILM NUMBER: 231490960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701541
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-417-5868
MAIL ADDRESS:
STREET 1: ONE MAIN STREET, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aset Therapeutics, Inc.
DATE OF NAME CHANGE: 20170321
4
1
form4-12152023_091215.xml
X0508
4
2023-12-15
0001701541
Black Diamond Therapeutics, Inc.
BDTX
0001202283
DIXON WENDY L
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 14TH FLOOR
CAMBRIDGE
MA
02142
true
false
false
false
0
Common Stock
2023-12-15
4
A
0
4043
2.73
A
34801
D
These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 14, 2023.
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
2023-12-15